GlassScriptPhysician profile
Yancy Jon Galutia
NPI 1316981848
$13,925.55
in general payments reported to CMS, 2019-2025
47 companies · $2,484 in 2025
The $2,484 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $919 · 2021: $2,424 · 2022: $2,019 · 2023: $2,234 · 2024: $2,518 · 2025: $2,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,170 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,170.37 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,552.41 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Novo Nordisk INC | $1,485.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,284.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,183.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $974.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $944.55 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $563.19 | 2019-2025 | Jardiance |
| Abbvie INC. | $550.21 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $506.51 | 2020-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $472.28 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $413.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $357.53 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $347.91 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $338.76 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $269.85 | 2022-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $251.58 | 2020-2025 | Livalo, Zoryve |
| Exact Sciences Corporation | $231.78 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $221.54 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $179.34 | 2019-2022 | |
| Corium, LLC | $140.82 | 2023-2024 | Azstarys |
| Esperion Therapeutics, INC. | $134.17 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $121.95 | 2022 | |
| Abbott Laboratories | $118.61 | 2024-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $110.74 | 2024-2025 | Voquezna |
| Eisai INC. | $107.98 | 2020-2025 | |
| Lundbeck LLC | $105.97 | 2024-2025 | Rexulti |
| Arbor Pharmaceuticals, INC. | $94.90 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $87.77 | 2021 | |
| Antares Pharma, INC. | $85.53 | 2020-2022 | |
| Genentech USA, INC. | $73.97 | 2019-2022 | |
| Kaleo, INC. | $70.59 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $67.66 | 2024-2025 | Rexulti |
| Currax Pharmaceuticals LLC | $65.50 | 2020-2022 | |
| Dexcom, INC. | $63.76 | 2023-2025 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $58.67 | 2019 | |
| Sumitomo Pharma America, INC. | $58.59 | 2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $40.50 | 2023 | Gvoke Hypopen |
| Biogen, INC. | $34.24 | 2021-2025 | Skyclarys |
| Boston Scientific Corporation | $22.04 | 2025 | Bodyguardian |
| Sanofi-Aventis U.S. LLC | $20.77 | 2019 | |
| Gilead Sciences, INC. | $20.43 | 2019 | |
| Abiomed | $19.42 | 2024 | Impella |
| Sanofi Pasteur INC. | $18.20 | 2023 | |
| Sun Pharmaceutical Industries INC. | $14.68 | 2020 | |
| Allergan, INC. | $14.01 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.53 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yancy Galutia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.